ac 220

Plogosertib (CYC140) is an orally active, selective, potent, and ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib exhibits antiproliferative and anticancer activity and can be used for the study of solid and hematologic tumors. and hematologic tumors.

Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.

HDAC3 BRD4-IN-1 (compound 26n) is an inhibitor of HDAC3 BRD4, exhibiting an IC50 of 8 nM for HDAC3, while its IC50 values for HDAC1 and HDAC2 are 220 nM and 120 nM, respectively. It displays anti-tumor and anti-proliferative effects by upregulating Ac-H3 and downregulating c-Myc. The half-life of HDAC3 BRD4-IN-1 in human liver microsomes is 29.36 minutes.

AC-42 hydrochloride is the hydrochloride salt form of AC-42. It acts as a conformational agonist of the muscarinic M1 receptor (muscarinic M1 receptor), exhibiting EC50 values of 805 nM and 220 nM on human wild-type and Y381A mutant M1 receptors, respectively. Additionally, AC-42 hydrochloride stimulates the accumulation of inositol phosphates (IP) and calcium mobilization in CHO cells.